February 26, 2026 - PRESSADVANTAGE - Silverback Webinar has announced the release of an expanded framework for its ...
And that was also presented at ASH 2025 and also a very, very strong data set. I should mention that BI-1808 that was monotherapy, single-agent therapy. Then, we also started our Phase IIa trial ...
General Atomics and Divergent to discuss cross-industry collaboration in a keynote address. I am very excited to hear ...
Beginner steps for Keynote on Mac for design and workflow; includes export to desktop or cloud and building a complete first deck ready to share ...
Alai is a pretty neat AI tool that really tries to make presentation creation less of a headache. What sets it apart, I think, is how it handles design options. Instead of just giving you one shot at ...
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a ...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the presentation of clinical and preclinical data from its Enzyme ...
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results